Incyte Q1 Results Miss Estimates

Incyte Corp. (INCY) on Tuesday reported a net income of $37.99 million or $0.17 per share for the first quarter, down from $53.54 million or $0.24 per share in the prior-year quarter.

Excluding items, adjusted net income for the quarter was $0.55 per share, compared to $0.67 per share in the year-ago quarter.

Total revenues for the quarter rose to $733.24 million from $604.72 million in the same quarter last year.

On average, analysts polled by Thomson Reuters expected the company to report earnings of $0.67 per share on revenues of $749.98 million for the quarter. Analysts' estimates typically exclude special items.

Looking ahead to fiscal 2022, Incyte now projects Jakafi net product revenue in a range of $2.33 billion to $2.40 billion. Other Hematology/Oncology net product revenues are projected between $210 million and $240 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Communications Commission or FCC has granted SpaceX Services, Inc. authorization to use its Starlink satellite internet system on vehicles in motion. SpaceX, owned by Elon Musk, is allowed to operate consumer and enterprise Ku-band Earth Stations in Motion or ESIM using frequencies allocated to the fixed satellite service. The approval would help the company to expand its services to Loud Muscle Science, LLC is recalling certain Launch Sequence products in the United States and Canada citing the presence of undeclared Tadalafil, the U.S. Food and Drug Administration said. These tainted Launch Sequence Capsule products are marketed as dietary supplements for male sexual enhancement. The U.S. Food and Drug Administration announced the intended availability of around 17 million bottles equivalent of general infant formula to be imported from New Zealand and Ireland. Under the FDA's enforcement discretion to source more infant formula to the U.S., French food company Danone SA will send 555,000 cans Aptamil Gold Plus from New Zealand.
Follow RTT